Recent Analysts’ Ratings Updates for Agilent Technologies (A)

A number of research firms have changed their ratings and price targets for Agilent Technologies (NYSE: A):

• 12/13/2024 – Agilent Technologies had its price target lowered by analysts at Bank of America Co. from $153.00 to $150.00. They now have a “neutral” rating on the stock.
• 12/9/2024 – Agilent Technologies had its price target lowered by analysts at Wells Fargo & Company from $157.00 to $155.00. They now have an “overweight” rating on the stock.
• 11/27/2024 – Agilent Technologies had its price target lowered by analysts at Barclays PLC from $145.00 to $135.00. They now have an “underweight” rating on the stock.
• 11/26/2024 – Agilent Technologies had its price target lowered by analysts at JPMorgan Chase & Co. from $165.00 to $160.00. They now have an “overweight” rating on the stock.
• 11/26/2024 – Agilent Technologies had its price target lowered by analysts at Sanford C. Bernstein from $140.00 to $135.00. They now have a “market perform” rating on the stock.
• 11/26/2024 – Agilent Technologies was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.

Agilent Technologies Trading Down 0.9 %

Shares of A traded down $1.21 during trading hours on Tuesday, hitting $136.46. 2,023,636 shares of the stock were exchanged, compared to its average volume of 1,722,679. Agilent Technologies, Inc. has a fifty-two week low of $124.16 and a fifty-two week high of $155.35. The business has a 50-day moving average of $136.63 and a 200-day moving average of $136.42. The firm has a market capitalization of $39.21 billion, a P/E ratio of 30.87, a price-to-earnings-growth ratio of 4.48 and a beta of 1.07. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.09 and a quick ratio of 1.58.

Agilent Technologies (NYSE:A) last released its earnings results on Monday, November 25th. The medical research company reported $1.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.41 by $0.05. Agilent Technologies had a net margin of 19.80% and a return on equity of 25.43%. The company had revenue of $1.70 billion for the quarter, compared to the consensus estimate of $1.67 billion. During the same quarter in the previous year, the company earned $1.38 EPS. Agilent Technologies’s quarterly revenue was up .8% compared to the same quarter last year. On average, research analysts expect that Agilent Technologies, Inc. will post 5.56 EPS for the current year.

Agilent Technologies Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 22nd. Shareholders of record on Tuesday, December 31st will be paid a $0.248 dividend. This represents a $0.99 dividend on an annualized basis and a dividend yield of 0.73%. This is a positive change from Agilent Technologies’s previous quarterly dividend of $0.24. The ex-dividend date is Tuesday, December 31st. Agilent Technologies’s dividend payout ratio (DPR) is 22.40%.

Insider Activity

In other Agilent Technologies news, SVP Dominique Grau sold 9,990 shares of Agilent Technologies stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $145.00, for a total transaction of $1,448,550.00. Following the transaction, the senior vice president now directly owns 40,011 shares of the company’s stock, valued at $5,801,595. The trade was a 19.98 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.33% of the company’s stock.

Institutional Trading of Agilent Technologies

A number of large investors have recently added to or reduced their stakes in the stock. Crewe Advisors LLC raised its stake in Agilent Technologies by 114.8% in the 2nd quarter. Crewe Advisors LLC now owns 189 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 101 shares during the period. Livelsberger Financial Advisory bought a new stake in shares of Agilent Technologies in the third quarter valued at approximately $28,000. Ridgewood Investments LLC purchased a new stake in shares of Agilent Technologies during the 2nd quarter valued at approximately $29,000. Ashton Thomas Securities LLC bought a new position in Agilent Technologies in the 3rd quarter worth approximately $31,000. Finally, Fortitude Family Office LLC grew its stake in Agilent Technologies by 68.3% in the 3rd quarter. Fortitude Family Office LLC now owns 234 shares of the medical research company’s stock valued at $35,000 after buying an additional 95 shares in the last quarter. Hedge funds and other institutional investors own 87.42% of the company’s stock.

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.